Fulminant neurologic manifestation of Systemic Lupus Erythematosus
Abstract
Keywords
Full Text:
PDFReferences
Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol 2013; 110(4):228–32 doi: 10.1016/j.anai.2012.12.010
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42(4):599–608. 10.1002/1529-0131(199904) 42:4<599:AID-ANR2>3.0.CO;2-F
Stock AD, Wen J, Putterman C. Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway. Front Immunol 2013; 4;484 doi: 10.3389/fimmu.2013. 00484.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methyl-prednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64(4):620–5.
Everett CM, Graves TD, Lad S, et al. Aggressive CNS lupus vasculitis in the absence of systemic disease activity. Rheumatology 2008; 47(1):107-109 doi:10.1093/rheumatology/kem264
Rizos T, Siegelin M, Hähnel S, Storch-Hagenlocher B, Hug A. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), Lupus 2009; 18:361-363;
Meroni PL, Tincani A, Sepp N, et al. Endothelium and the brain in CNS lupus. Lupus 2003; 12(12):919-28; DOI: 10.1191/0961203303 lu503oa.
DOI: http://dx.doi.org/10.22551/2014.04.0103.10024
Copyright (c)
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975